| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Tandem Diabetes Care (NASDAQ:TNDM) reported its Q4 earnings results on Wednesday, February 21, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Tandem Diabetes Care missed estimated earnings by 8.0%, reporting an EPS of $-0.27 versus an estimate of $-0.25.
Revenue was down $23.71 million from the same period last year.
Last quarter the company missed on EPS by $0.04 which was followed by a 14.37% drop in the share price the next day.
Here's a look at Tandem Diabetes Care's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.34 | -0.53 | -0.52 | -0.06 |
| EPS Actual | -0.38 | -0.30 | -0.63 | -0.01 |
| Revenue Estimate | 192.34M | 197.64M | 170.23M | 221.83M |
| Revenue Actual | 185.62M | 195.92M | 169.38M | 220.50M |
To track all earnings releases for Tandem Diabetes Care visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TNDM
